- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
Bavarian Nordic
Market Cap: DKK 14.8b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 193.50
7D
5.9%
1Y
-18.9%
H. Lundbeck
Market Cap: DKK 42.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 40.64
7D
-3.2%
1Y
3.4%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 296.65
7D
-0.5%
1Y
-16.7%
H. Lundbeck
Market Cap: DKK 42.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 40.35
7D
12.7%
1Y
22.5%
Gubra
Market Cap: DKK 6.5b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 385.00
7D
1.1%
1Y
4.1%
Strategic Partners
Market Cap: DKK 28.8m
Does not have significant operations.
STRAP
DKK 680.00
7D
-2.9%
1Y
-34.9%